{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["10(4)"],"submitter":["Brcic L"],"pubmed_abstract":["<h4>Background</h4>Programmed cell death 1/programmed death ligand 1 (PD-1/PD-L1) immune-checkpoint blockade is a promising new therapeutic strategy in cancer. However, expression patterns and prognostic significance of PD-L1 and PD-1 are still controversial in human malignant pleural mesothelioma (MPM).<h4>Methods</h4>Formalin-fixed paraffin-embedded (FFPE) tumor samples from 203 MPM patients receiving standard treatment without immunotherapy were collected from 5 European centers. PD-L1 and PD-1 expression of tumor cells (TCs) and tumor-infiltrating lymphocytes (TILs) were measured by immunohistochemistry and correlated with clinical parameters and long-term outcome.<h4>Results</h4>High (>10%) PD-L1 TC and PD-1 TILs expressions were found in 18 (8%) and 39 (24%) patients, respectively. PD-L1 was rarely expressed by TILs [≥1%, n=13 (8%); >10%, n=1]. No significant associations were found between the PD-L1 or PD-1 expression of TCs or TILs and clinicopathological parameters such as stage or histological subtype. Notably, patients with high (>10%) TC-specific PD-L1 expression exhibited significantly worse median overall survival (OS) (6.3 <i>vs.</i> 15.1 months of those with low TC PD-L1 expression; HR: 2.51, P<0.001). In multivariate cox regression analysis adjusted for clinical parameters, high TC PD-L1 expression (>10%) proved to be an independent negative prognostic factor for OS (HR: 2.486, P=0.005). There was no significant correlation between PD-L1 or PD-1 expression of TILs and OS.<h4>Conclusions</h4>In this multicenter cohort study, we demonstrate that high (>10%) PD-L1 expression of TCs independently predicts worse OS in MPM. Further studies are warranted to investigate the value of PD-L1/PD-1 expression as a marker for treatment response in MPM patients receiving immunotherapy."],"journal":["Translational lung cancer research"],"pagination":["1594-1607"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8107750"],"repository":["biostudies-literature"],"pubmed_title":["Prognostic impact of PD-1 and PD-L1 expression in malignant pleural mesothelioma: an international multicenter study."],"pmcid":["PMC8107750"],"pubmed_authors":["Cufer T","Hegedus B","Mohorcic K","Jakopovic M","Laszlo V","Renyi-Vamos F","Hoda MA","Klikovits T","Mosleh B","Rozman A","Gieszer B","Klepetko W","Grusch M","Samarzija M","Kern I","Jakubec P","Hritcu R","Fischer O","Skarda J","Buder A","Megyesfalvi Z","Brcic L","Seiwerth S","Fillinger J","Filipits M","Hoetzenecker K","Kolek V","Berger W","Sinn K","Bilecz A","Dome B"],"additional_accession":[]},"is_claimable":false,"name":"Prognostic impact of PD-1 and PD-L1 expression in malignant pleural mesothelioma: an international multicenter study.","description":"<h4>Background</h4>Programmed cell death 1/programmed death ligand 1 (PD-1/PD-L1) immune-checkpoint blockade is a promising new therapeutic strategy in cancer. However, expression patterns and prognostic significance of PD-L1 and PD-1 are still controversial in human malignant pleural mesothelioma (MPM).<h4>Methods</h4>Formalin-fixed paraffin-embedded (FFPE) tumor samples from 203 MPM patients receiving standard treatment without immunotherapy were collected from 5 European centers. PD-L1 and PD-1 expression of tumor cells (TCs) and tumor-infiltrating lymphocytes (TILs) were measured by immunohistochemistry and correlated with clinical parameters and long-term outcome.<h4>Results</h4>High (>10%) PD-L1 TC and PD-1 TILs expressions were found in 18 (8%) and 39 (24%) patients, respectively. PD-L1 was rarely expressed by TILs [≥1%, n=13 (8%); >10%, n=1]. No significant associations were found between the PD-L1 or PD-1 expression of TCs or TILs and clinicopathological parameters such as stage or histological subtype. Notably, patients with high (>10%) TC-specific PD-L1 expression exhibited significantly worse median overall survival (OS) (6.3 <i>vs.</i> 15.1 months of those with low TC PD-L1 expression; HR: 2.51, P<0.001). In multivariate cox regression analysis adjusted for clinical parameters, high TC PD-L1 expression (>10%) proved to be an independent negative prognostic factor for OS (HR: 2.486, P=0.005). There was no significant correlation between PD-L1 or PD-1 expression of TILs and OS.<h4>Conclusions</h4>In this multicenter cohort study, we demonstrate that high (>10%) PD-L1 expression of TCs independently predicts worse OS in MPM. Further studies are warranted to investigate the value of PD-L1/PD-1 expression as a marker for treatment response in MPM patients receiving immunotherapy.","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Apr","modification":"2025-04-04T21:24:47.781Z","creation":"2025-04-04T21:24:47.781Z"},"accession":"S-EPMC8107750","cross_references":{"pubmed":["34012777"],"doi":["10.21037/tlcr-20-1114"]}}